[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,377
Citations 0
From The Medical Letter on Drugs and Therapeutics
February 10, 2015

Invokamet and Xigduo XR – Two New Combinations for Type 2 Diabetes

JAMA. 2015;313(6):620-621. doi:10.1001/jama.2015.349

The FDA has approved fixed-dose combinations of metformin with either canagliflozin (Invokamet) or dapagliflozin (Xigduo XR) (Table) for treatment of patients with type 2 diabetes not adequately controlled with any one of these drugs, or in those already being treated with both metformin and either canagliflozin or dapagliflozin (Box).

Metformin decreases hepatic glucose production and, to a lesser extent, increases peripheral glucose uptake. Canagliflozin and dapagliflozin inhibit SGLT2 (sodium-glucose co-transporter 2); they decrease renal glucose reabsorption, thereby increasing urinary glucose excretion.

First Page Preview View Large
First page PDF preview
First page PDF preview
×